Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Leukemia, B-Cell × obinutuzumab × Clear all

Phase

Status

Active not recruiting 3 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 30 Lymphoma, Follicular 16 Lymphoma, Non-Hodgkin 14 Lymphoma 10 Lymphoma, Mantle-Cell 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma, B-Cell, Marginal Zone 6 Lymphoma, B-Cell 5 Recurrence 4 Neoplasms 2 Leukemia, Hairy Cell 2 Waldenstrom Macroglobulinemia 1 Uveal Melanoma 1 Tumor Lysis Syndrome 1 Solid Cancers 1 Oncology Patients Receiving Chemotherapy 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Melanoma 1 Leukemia, Prolymphocytic, B-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphoid 1 Leukemia, B-Cell 1 Leukemia 1 Disease 1 Colorectal Neoplasms 1 Chromosome 17 deletion 1 Carcinoma, Non-Small-Cell Lung 1 Bronchiolitis Obliterans Syndrome 1 Anemia 1

Interventions

ofatumumab 10 Rituximab 6 ibrutinib 5 Cyclophosphamide 5 fludarabine phosphate 4 Bendamustine Hydrochloride 4 fludarabine 3 Lenalidomide 3 Alemtuzumab 3 spebrutinib 2 navitoclax 2 acalabrutinib 2 KW-2478 2 venetoclax 1 tirabrutinib 1 obinutuzumab 1 idelalisib 1 dinaciclib 1 Tablets 1 Stem Cell Transplantation 1 Rabeprazole 1 Pentostatin 1 Metronidazole 1 Methylprednisolone 1 Magnetic Resonance Imaging 1 Leukapheresis 1 Lansoprazole 1 Itraconazole 1 Immunotherapy, Adoptive 1 Hsp90 inhibitor KU757 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03787264 2024-12-30

CLL2-BAAG

German CLL Study Group

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡